Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986504
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-986504 is an orally bioavailable small molecule inhibitor of diacylglycerol kinase alpha (DGKα) and zeta (DGKζ), currently under development by Bristol Myers Squibb for the treatment of advanced solid tumors. DGKα and DGKζ are enzymes that metabolize diacylglycerol (DAG), a critical second messenger in T-cell activation, into phosphatidic acid. By inhibiting these enzymes, BMS-986504 aims to sustain high levels of DAG at the immunological synapse, thereby enhancing T-cell receptor signaling and effector function. This mechanism is intended to reverse T-cell anergy and exhaustion within the immunosuppressive tumor microenvironment, potentially improving the efficacy of immune checkpoint inhibitors like nivolumab.
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on BMS-986504.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986504.